NCT06947811View on ClinicalTrials.gov

A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Interventions
DRUG

Almonertinib

Patients will be treated with Almonertinib, 110 mg p.o., daily

DRUG

Palbociclib

Patients will be treated with Palbociclib, 125 mg(dose determined from Part one of study) p.o., daily

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER